Loading page…

Report overview

The report records 2018 revenue of DKK 10,410 million and describes LEO Pharma's agreement to acquire Bayer's prescription dermatology unit, with the US business integrated during the year. It reports achieving ISO 14001 certification at all five manufacturing sites and completing a company-wide carbon-footprint analysis. The report also describes continued investment in the company's dermatology strategy and pipeline.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2018
Period: 1 January 2018 – 31 December 2018
Publication date: 26 February 2019
Language
Pages
File size

Standards & Assurance

Standards

Other

Commitments

UN Global Compact
UN Guiding Principles
Science Based Targets initiative

Assurance

Statement included

ESG & Materiality

ESG data

Indicators available in this report:

Employees
Women on the board

Materiality

Assessment
Basis

Build your research dataset.

Original reports, structured indicators and machine-readable Markdown for your project.

Explore our services